DNA-DIRECTED EFFECTS OF FdUMP(N)

FdUMP(N) 的 DNA 定向效应

• 批准号: 7263975
• 负责人: William H Gmeiner
• 金额: $ 30.61万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-10 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7263975
• 关键词: Active Biological Transport; Affinity; Amino Acid Sequence; Antineoplastic Agents; Apoptotic; Binding; Biological Assay; Biological Models; Camptothecin; Cancer cell line; Cell Cycle Arrest; Cell Death; Cell Line; Cell model; Cells; Cessation of life; Charge; Chemicals; Class; Clinical Trials; Collaborations; Colon Carcinoma; Complex; Confocal Microscopy; DNA; DNA Damage; DNA Double Strand Break; DNA Single Strand Break; DNA-protein crosslink; DU145; Data; Data Analyses; Deoxyglucose; Dependence; Development; Exclusion; Exposure to; FdUMP(10); Flow Cytometry; Fluorodeoxyuridylate; Fluorouracil; Goals; Head; Human; Immunohistochemistry; Isopropanol; Kinetics; Label; Laboratories; Length; Malignant Neoplasms; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Mass Spectrum Analysis; Measures; Mediating; Metabolic; Metabolism; Multienzyme Complexes; NMR Spectroscopy; Nuclear; Nucleotides; Nude Mice; PC3 cell line; Pathway interactions; Peptide Sequence Determination; Pharmaceutical Preparations; Poison; Precipitation; Primer Extension; Process; Property; Prostate; Prostatic Epithelium; Proteins; Publishing; Pulsed-Field Gel Electrophoresis; Qualifying; Radioactivity; Rapid Access to Intervention Development; Refractory; Relative (related person); Reporting; Research; Research Personnel; Research Project Grants; Scintillation Counting; Site; Sodium Azide; Staging; Structure; Structure-Activity Relationship; Techniques; Thymidylate Synthase; Time; Transport Process; Treatment Protocols; Trypan Blue; Type I DNA Topoisomerases; Work; base; cancer cell; capecitabine; chemotherapy; computerized data processing; crosslink; cytotoxic; cytotoxicity; density; fluoropyrimidine; hepatoma cell; human TOP1 protein; in vivo; inhibitor/antagonist; innovation; insight; novel; pre-clinical; programs; prototype; receptor mediated endocytosis; size; tumor xenograft; uptake

DESCRIPTION (provided by applicant): FdUMP[N] compounds constitute a novel class of fluoropyrimidine (FP) chemotherapeutic that may be useful for the treatment of human malignacies that are refractory to current chemotherapy. The goal of this research project is to understand the unique cytotoxic mechanism of FdUMP[N] compounds. Human prostate cancer (PC) cells will be used as a model system to investigate FdUMP[N] cytotoxicity because of the relative sensitivity of PC cells to FdUMP[10], and because of the need for new and more effective drugs to treat late-stage PC. PC results in nearly 30,000 deaths in the U.S. each year. Aim 1 focuses on evaluating the extent that FdUMP[N] multimers enter PC cells via active transport and identifying proteins expressed by PC cells that are involved in receptor-mediated endocytosis. Cellular uptake kinetics will be determined from the time- and concentration-dependence of radioactivity in PC cellular lysates following exposure to 32P-labeled FdUMP[N] compounds. The contribution of active transport to cellular uptake will be evaluated using metabolic inhibitors. Structure/function analyses will be performed to identify structural features of FdUMP[N] compounds that promote intracellular internalization of FdUMP[N] compounds via active transport. Protein(s) involved in the active transport of FdUMP[N] compounds will be identified by UV cross-linking, and sequences for these protein(s) will be determined using mass spectrometry. In Aim 2, the intracellular metabolism of [6-3H]FdUMP[N] compounds to monomeric FP metabolites will be evaluated, and thymidylate synthase inhibition and nucleotide pool imbalances will be quantified. In Aim 3, the misincorporation of FdUTP into DNA and the extent and type of DMA damage, including DNA damage resulting from topoisomerase I cleavage complex formation, will be quantified using alkaline elution, pulsed-field gel electrophoresis, and an in vivo complex of enzyme bioassay. These studies greatly enrich our understanding of the unique cytotoxic mechanism for FdUMP[N] compounds towards PC cells.

说明书(申请人提供)：FdUMP[N]化合物构成了一类新的氟嘧啶(FP)化疗药物，可用于治疗对当前化疗无效的人类恶性肿瘤。本研究的目的是了解FdUMP[N]化合物独特的细胞毒性机制。人前列腺癌(PC)细胞将被用作研究FdUMP[N]细胞毒性的模型系统，因为PC细胞对FdUMP[10]相对敏感，并且需要新的更有效的药物来治疗晚期PC。在美国，个人电脑每年导致近3万人死亡。目的1评估FdUMP[N]多聚体通过主动转运进入PC细胞的程度，并鉴定PC细胞表达的参与受体介导的内吞作用的蛋白质。细胞摄取动力学将根据暴露于32P标记的FdUMP[N]化合物后PC细胞裂解物中放射性的时间和浓度依赖性来确定。主动转运对细胞摄取的贡献将使用代谢抑制剂进行评估。将进行结构/功能分析，以确定FdUMP[N]化合物的结构特征，这些结构特征通过主动转运促进FdUMP[N]化合物在细胞内的内化。参与FdUMP[N]化合物主动转运的蛋白质(S)将通过紫外光交联来鉴定，这些蛋白质(S)的序列将使用质谱学来确定。在目标2中，将评估[6-~3H]FdUMP[N]化合物的胞内代谢为单体FP代谢物，并将量化胸苷合成酶抑制和核苷酸池失衡。在目标3中，将使用碱性洗脱、脉冲场凝胶电泳法和体内酶生物测定复合体来定量FdUTP与DNA的错误结合以及DMA损伤的程度和类型，包括拓扑异构酶I裂解复合体形成造成的DNA损伤。这些研究极大地丰富了我们对FdUMP[N]化合物对PC细胞独特的细胞毒作用机制的理解。